New WGS/WES workflows compatible with latest versions of GATK and available through web-based evaluations.
Redwood City, CA (PRWEB) October 22, 2013
Bina Technologies, the genomic big data science company accelerating personalized medicine, today announced the general availability of its all-new RNA-Seq analysis capabilities. This new application delivers fast, accurate and scalable analysis of RNA-Seq datasets on top of the company’s Bina Genomic Analysis Platform.
Recent advances in utilizing Next-Gen Sequencing (NGS) for transcriptomics have proved to be highly precise compared to traditional microarray methods. To take full advantage of these developments, the Bina Platform has built-in capabilities that process up to 1,000 RNA-Seq samples per month, a considerable upgrade in scalability and speed of analysis over current solutions. Now fully integrated with whole genome, exome and RNA-Seq capabilities, the Bina Genomic Analysis Platform delivers the most complete end-to-end solution for high-throughput genomic analysis available today.
“Today’s traditional methods for handling RNA-Seq suffer from low quality and slow turnaround times,” said Narges Bani Asadi, founder and CEO of Bina Technologies. “With the addition of accelerated RNA-Seq to our suite of whole genome and exome accelerated workflows, researchers and clinicians can now better employ a mixture of NGS samples and analysis pipelines in their discovery and development programs — quickly, accurately and at scale — while still managing costs tightly.”
The standard Bina RNA-Seq workflow includes several widely-adopted, open-source software tools such as TopHat2, Bowtie2, and Cufflinks. It also includes support for multiple sample merging, an important feature than enhances transcript identification.
Another significant, new feature of the Bina Platform is its compatibility with several newer versions of the Genomic Analysis Toolkit (GATK) suite of software tools developed by The Broad Institute. For whole genome and exome samples, Bina has now extensively tested and validated the Bina Platform with all versions of GATK from v1.6 to v2.7, including GATK Lite. This flexibility allows researchers to analyze their data more quickly and accurately while taking advantage of the many recent improvements of GATK.
“Genomic analysis is complex, and the stakes are high,” said Asadi. “For us, the goal has always been to deliver a fully integrated and robust solution. We’re confident that the Bina Platform will help significantly accelerate genomic analysis and empower users to gain even greater insights into disease causes.”
In addition to this announcement, Bina is unveiling a new web-based program called Test Drive that allows researchers to use their own well-characterized whole genome, whole exome, and RNA samples in order to evaluate the Bina Genomics Analysis Platform. “The Bina ‘Test Drive’ program allows researchers to experience the power and performance of the Bina Platform for themselves,” said Mark Sutherland, SVP of Business Development at Bina.
To begin your own ‘Test Drive’ today, please visit: http://www.binatechnologies.com/test-drive-bina-platform.
The Bina team will be demonstrating these new features during the American Society of Human Genetics (ASHG) meeting in Boston, from October 22nd-26th. Please visit the Bina team in Booth #503 in the main exhibition hall of the Boston Convention & Exhibition Center.
To learn more about Bina Technologies, please visit: http://binatechnologies.com.
About Bina Technologies
Bina is the big data science platform accelerating personalized medicine for researchers and clinicians requiring fast, accurate and scalable genomic analysis. We develop cutting-edge big data technologies to dramatically reduce the amount of time and money required to process raw genetic data in order to generate insights for personalized medicine.
Founded in 2011, Bina was started by a team of Stanford and Berkeley researchers and entrepreneurs, with the vision that whole genome sequencing (WGS) is just the beginning of a brighter future. Bina is accelerating personalized medicine, one genome at a time.
We are a team of data scientists, bioinformaticians, software developers and high performance computing experts working in harmony in Redwood City, California. To learn more, visit: http://binatechnologies.com.